Tirzepatide significantly improves health-related quality of life and physical functioning compared with dulaglutide in ...

High-dose tirzepatide is associated with superior HbA1c reduction and weight loss compared with semaglutide in type 2 ...

Phase 3 trial data show a synthetic semaglutide injection provides glycemic control comparable to Ozempic in patients with ...

Teplizumab is now approved for children as young as 1 year with stage 2 type 1 diabetes, following study results on safety and pharmacokinetics.

Orforglipron significantly reduces body weight across all BMI categories in the ATTAIN-1 trial, with results presented at ...

Veligrotug yields rapid and substantial reductions in proptosis for adults with active thyroid eye disease, according to ...

Once-weekly lonapegsomatropin shows sustained safety and efficacy up to 90 weeks in adults with GHD, according to AACE 2026 ...

Crinecerfont allows for significant glucocorticoid dose reductions in adults with classic CAH while maintaining androgen control.

The FDA will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.

Patients with hematologic malignancies have an increased risk for cardiovascular disease (CVD) compared with the general population.

One in 4 US adults report using artificial intelligence tools or chatbots for physical or mental health information.

Nine of 10 adults in the United States report having had a source of usual health care in 2024, according to new data.